## Prognostic Factors in Endometrial Carcinoma: Hierarchy and Clinical Significance **Key Point:** **FIGO stage is the most important prognostic factor in endometrial carcinoma**, not histological grade. While grade is important, stage supersedes it in determining prognosis and treatment. ### Prognostic Factors in Endometrial Carcinoma | Factor | Impact | Clinical Significance | |--------|--------|----------------------| | **FIGO Stage** | **Most important** | Determines overall survival more than any other single factor | | **Histological Grade** | Important but secondary | Grade 1 (well-differentiated) has better prognosis than Grade 3 (poorly differentiated), but stage is more predictive | | **Lymphovascular Invasion (LVI)** | Independent adverse factor | Present in ~15–20% of early-stage cases; warrants adjuvant therapy even in stage IA | | **Myometrial Invasion Depth** | Stage-defining | Stage IB (>50% invasion) vs IA (≤50% invasion); influences treatment | | **Molecular Subtype** | Emerging prognostic tool | POLE mutations = ultrahigh-risk; MMR-deficient = intermediate-risk; TP53-mutant = high-risk | | **Tumor Size** | Modest impact | Large tumors (>2 cm) associated with worse outcomes | | **Cervical Stromal Invasion** | Stage-defining | Stage II; worsens prognosis | **High-Yield:** The **FIGO 2009 staging system** is based on surgical findings (myometrial invasion, cervical involvement, adnexal involvement, peritoneal/distant metastases). A stage III tumor with grade 1 histology has **worse prognosis** than a stage I grade 3 tumor, because stage reflects extent of disease spread. ### Why "Grade Is Superior to Stage" Is Incorrect Histological grading (FIGO grade 1, 2, or 3) is a **morphologic assessment of differentiation** and is important for prognosis, but it is **subordinate to stage** in determining survival outcomes. Large prospective studies and meta-analyses consistently show that **stage is the single most powerful independent predictor of survival** in endometrial carcinoma. A grade 3 stage IA tumor has better prognosis than a grade 1 stage III tumor. **Clinical Pearl:** In clinical practice, a stage I endometrial carcinoma with high-risk features (grade 3, LVI, outer-third myometrial invasion, or molecular high-risk profile) may receive adjuvant radiotherapy or chemotherapy, whereas a stage III grade 1 tumor will almost always receive multimodal adjuvant therapy, regardless of grade. **Mnemonic: "STAGE > GRADE"** — When deciding prognosis and treatment intensity in endometrial cancer, stage (extent of spread) trumps grade (histologic appearance). **Warning:** Do not confuse "grade is important" (true) with "grade is more important than stage" (false). Grade influences treatment within a stage, but stage determines the baseline prognosis. [cite:Robbins 10e Ch 22]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.